Globeflex Capital L P Makes New $2.54 Million Investment in Amneal Pharmaceuticals, Inc. $AMRX

Globeflex Capital L P bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 146,508 shares of the company’s stock, valued at approximately $2,536,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMRX. Intech Investment Management LLC increased its stake in shares of Amneal Pharmaceuticals by 1.2% in the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after buying an additional 1,159 shares during the period. Hsbc Holdings PLC boosted its position in Amneal Pharmaceuticals by 1.6% during the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after buying an additional 1,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Amneal Pharmaceuticals by 2.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after acquiring an additional 1,582 shares during the last quarter. Comerica Bank grew its holdings in Amneal Pharmaceuticals by 56.1% during the 4th quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after acquiring an additional 1,685 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in Amneal Pharmaceuticals in the 4th quarter valued at approximately $26,000. 31.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on AMRX shares. Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, August 12th. UBS Group increased their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $21.00 target price on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Finally, Zacks Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $17.67.

Insiders Place Their Bets

In other news, EVP Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the completion of the transaction, the executive vice president directly owned 253,390 shares of the company’s stock, valued at approximately $4,436,858.90. This trade represents a 36.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jason B. Daly sold 210,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the transaction, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This represents a 85.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 413,016 shares of company stock worth $7,216,567. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $17.91 on Monday. The company’s 50 day moving average price is $17.52 and its 200-day moving average price is $14.74. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. Amneal Pharmaceuticals, Inc. has a 52-week low of $9.20 and a 52-week high of $19.26. The company has a market capitalization of $5.72 billion, a P/E ratio of 36.55 and a beta of 1.27.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The company had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.